Abdominal Aortic Aneurysm (AAA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Abdominal Aortic Aneurysm (AAA) Market Outlook

Thelansis’s “Abdominal Aortic Aneurysm (AAA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Abdominal Aortic Aneurysm (AAA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Abdominal Aortic Aneurysm (AAA) Overview

An Abdominal aortic aneurysm (AAA) is characterized by the enlargement of the lower segment of the aorta, the body’s primary blood supply vessel, which extends from the heart through the chest and abdomen. Several factors contribute to the formation of AAA, including inflammation weakening the aortic artery wall, advanced age (50+ for men, 60+ for women), a history of atherosclerosis, high blood pressure, elevated cholesterol, heart or peripheral vascular disease, and tobacco use. Those at the highest risk are men older than 60, smokers, Caucasians, and individuals with a first-generation relative who has had an AAA. Additional potential factors associated with AAA development include tears in the arterial wall, infections, and congenital connective tissue disorders. The diagnosis of an abdominal aortic aneurysm typically involves the use of ultrasound. However, a CT scan is required to determine its precise location, size, and impact on surrounding blood vessels, especially in symptomatic patients. The differential diagnosis for AAA includes Mesenteric ischemia, Peptic ulcer disease, Diverticulitis, Pyelonephritis, and Myocardial infarction. Treatment is recommended when the aneurysm diameter reaches 5 to 5.5 cm, shows rapid enlargement of more than 0.5 cm over six months, or becomes symptomatic. Open surgical repair via transabdominal or retroperitoneal approach has been the gold standard. The prognosis for AAA is grim, with an approximately 80% risk of death following a rupture. Most patients do not survive long enough to reach the hospital, and even with surgical intervention, the success rate for repairing a ruptured aneurysm is only 50%.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Abdominal Aortic Aneurysm (AAA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034